Painchek Ltd · ASX:PCK
Painchek — Earnings Presentation (May 2025)
32 slides from Painchek's earnings presentation, May 1, 2025
Slide 1: Quarterly update April 2025
For personal use only Q uarterly up date April 2 025 P H I L I P D A F F A S , C EO & M D P A I N C H E K L TD | A S X : PC K 1 |
Slide 2: Our purpose is to give a voice to people who cannot verbalise pain
For personal use only Our purpose is to give a voice to people who cannot reliably verbalise their pain
Slide 3: The Problem: Inadequate Pain Assessment in Non-Verbal Patients
The Problem: Inadequate Pain Assessment in Non-Verbal Patients US Federal and Local Requirements* for Compliance, Reimbursements and Quality Rating require Pain Management & Assessment Solutions for non-verbal Patients For personal use only PainChek’s AI-enabled digital-first Pain Assessment solutio
Slide 4: The Breadth of PainChek's Global Market Opportunity
T HE B REA D TH OF P AI NC HEK ’s G LOB AL MA RKET OP PO RTUNITY For personal use only 400M pre-verbal children1 25-42% of hospital beds occupied by people with dementia4,5 57M people living with dementia >150M expected by 20502,3 1. Ecology Communications Group. www.ecology.com/birth-death-rates 4.
Slide 5: PainChek Global Market Strategy
P AINC HEK GL OB AL MA RKET STR ATEG Y For personal use only B U SI N E SS M O D E L TARGET MARKETS/USERS B2B Enterprise: licence • Dementia &/geriatric wards • Hospitals • ER/Post surgical care • Care Homes • Residential & home care providers • Home care He althcare • Primary Care PainChek Profe ss
Slide 6: PainChek Adult Global Market Opportunity
P AINC HEK ADULT G LOB AL MA RKET OP PO RTUNITY LONG TERM CARE MARKET VALUE For personal use only Aus UK US ROW est TOTAL No. Aged Care Beds 0.22m 0.54m 1.7m 4.5m 6.96m Annual Market Value @ A$4 per bed per A$11m A$26m A$100m A$216m A$350m month PainChek Adult HOME CARE/CONSUMER MARKET VALUE Aus EU
Slide 7: The PainChek Universal App: Quick and Easy Operation
THE P AINC HEK ® UNIVERS AL A PP : QUIC K A ND EAS Y OPE RA TIO N AI based micro-facial pain expression analysis: For personal use only Software-as-a- A medical • 3 second scan of patient face Medical Device device in • Recognises 9 micro-facial enables mobile your pocket expressions indicative of p
Slide 8: PainChek Analytics
P AI NC HEK A NA LYTI C S Through PainChek®'s web portal, care managers can access real time dashboard reporting and data analytics to help draw actionable insights and assist their team in reducing clinical risk while improving their quality of care. For personal use only Pain data trends are graph
Slide 9: FDA De Novo Clearance Projected Q2
FDA DE N OVO C LEA RA NC E PROJEC TED Q2 202 5 For personal use only US FDA de Novo Positive review Potential FDA Validation Study meeting held with clearance for delivers positive FDA in April - one PainChek’s adult results more meeting to app also provides a be scheduled in the predicate for its u
Slide 10: March Quarterly Highlights
MAR C H 202 5 QUAR T ER LY HI G HL IG HT S: US FD A C L EAR ANC E ON TR AC K PO ST FD A MEET I NG , I MPL EMEN TA T IO N GR OWT H & POS I TI V E I NF ANT AP P P RO GR ESS For personal use only FDA clearance & US Continued acceleration Direct to parent market commercial market in growth of PainChek e
Slide 11: PainChek across Australia
PainChek across Australia Aged care’s most popular digital clinical tool with large growth opportunities • PainChek commercial licenses cover around 60,000 beds and 750 NOTABLE EXISTING AUSTRALIAN AGED CARE CLIENTS aged care homes, around 32% of total AU RAC market and now (COVERING 25,000+ BEDS) en
Slide 12: PainChek Growing UK Footprint
PainChek Growing UK Footprint in a 500,000 bed Aged Care market • PainChek commercial licences in UK aged care cover NOTABLE EXISTING UK AGED CARE CLIENTS more than 39,000 aged care beds and 1,000 care COVERING 12,500 BEDS. For personal use only homes. • Implemented licences reach 24,000 – 80% growt
Slide 13: PainChek Penetrating UK Acute Care Market (Hospitals)
P AI NC HEK PE NET R AT I NG UK AC UTE CARE MARKET (HO SPITAL S) • PainChek commenced the Edinburgh Royal Infirmary pilot in April 2025 to For personal use only build an economic business case for rollout across a potential 21 hospitals in the region. • An integration with TrakCare EMR system (Inter
Slide 14: PainChek's Growing Footprint in Canadian Market
P AINC HEK’S GR OWING F OOTP RIN T IN C AN ADIAN MAR KET PainChek has begun the commercialisation of the Canadian market, converting initial pilot clients into long term commercial agreements. Selling, training and support was all provided remotely from Australia, with a local team to be built out e
Slide 15: Clinical Outcomes from Devonshire Dementia Care Home - UK
CLINICAL OUTCOMES FROM DEVONSHIRE DEMENTIA CARE HOME - UK Devonshire Dementia Care Home in Surrey is a specialist dementia care home and day centre. PainChek®’s effectiveness was evaluated over four months at the home from August to November 2024. Residents’ pain indicators were analysed for changes
Slide 16: PainChek qualified pipeline exceeds 40,000 new licences
PainChek qualified pipeline exceeds 40,000 new licences – potentially doubling current ARR Contracted ARR $4.9M + Current Pipeline ARR $1.8M $6.7M Projected ARR 160,000 For personal use only $1.3M ARR 140,000 29,000 120,000 $0.5M ARR $1.5M ARR 12,000 100,000 Existing 29,816 pipeline 80,000 $3.4M ARR
Slide 17: Consistent Growth in Clinical Utility - World's Largest Pain Database
C ONS I ST ENT GR OW T H I N C LI N IC AL U TI L I TY – WOR LD’ S LA RG EST PA IN DATABA SE For personal use only CU MUL ATI VE N UM BE R OF PAI NCH EK ® ASSE SSME NT S Over 10.2 million global pain assessments as 12,000,000 of December 2025 conducted on the 10,270,000 PainChek platform across more
Slide 18: Strong Global Traction
Strong Global Traction: Implemented as a Medical Device in Senior Care Facilities Worldwide Canada Europe (EU) For personal use only • Regulatory cleared & patent secured • 300,000 aged care bed market • German market: Collaborative agreement with the University of Applied Sciences and Arts (HSBI) •
Slide 19: US Market Entry Activities Progressing Positively
U S MAR K ET ENT R Y AC T IV I T I ES P RO GR ESS IN G P OSI T I V ELY For personal use only Positive Client engagement during PointClickCare (PCC) US client conference April 2025 - PCC provide access to 1,000,000 North American Aged Care beds FDA clinical data presentations at US based conferences
Slide 20: Meet PainChek Infant
For personal use only Meet PainChek® Infant A PainChek Limited Product 20
Slide 21: Pre-verbal Children's Pain Assessment Is a Large Global Market Opportunity
P RE-VER BAL CH ILDR EN’S PAIN A SSE SSMEN T IS A L AR GE G LOB AL MA RKET OP PO RTUNITY CONSUMER PRE-VERBAL CHILDREN MARKET VALUE For personal use only Indicative App Price A$10/month Net Revenue A$7/month after app store commissions No. 0-3 year olds Worldwide 400m No. Infants 0-1 year worldwide 1
Slide 22: Meet PainChek Infant
M EE T P AI NC HE K ® I N F AN T For personal use only • The newest addition to the PainChek family, PainChek Infant, is the world’s first AI- enabled app for instant pain assessment on infants aged 1-12 months • Designed for in-home use by parents or other non-medical carers • Globally, the Infant
Slide 23: PainChek Children's Market Strategy
PainChek Children’s Market Strategy - to access 400 million pre-verbal children worldwide For personal use only B2C Consumer B2B HCP Partnership Market Market Market Parents Integrations Hospital OTs Family Pharma Daycare GPs MedTech • Ambassadors • HCP Customers • Baby Monitors Channels • Social Me
Slide 24: Meet PainChek Infant
M EE T P AI NC HE K ® I N F AN T For personal use only PainChek® Infant app is designed with parents and families in mind, offering a comprehensive user-friendly experience with a range of valuable features including: 3-second facial analysis-based pain assessment Monitoring of historical pain event
Slide 25: PainChek Infant - Recent Milestones & Key Updates
PainChek Infant – Recent Milestones & Key Updates App Live! Kiindred App Store User What’s next? For personal use only Promotion stats generated content PainChek Infant app 133+ consumers Initial phase is a soft 4 x videos created by Implement key is live in the iOS app applied to download launch in
Slide 26: Smart medical AI apps for Smart Parenting
Smart medical AI apps utilising smart devices for Smart Parenting For personal use only Vocalisation Facial Analysis • Microphone analysis • Instant assessments – • Cry of pain or no pain 3 seconds to scan face • Smart phone "Shazam" • Log treatments version • Diarise events • Integration with baby
Slide 27: Infant Pain Care Strategy
Infant Pain Care Strategy For personal use only Screen Assess Treat Monitor • Vocalisation AI feature • Facial AI analysis • Intervention • Facial AI analysis ▪ Cry/No Cry ▪ Multi- • Pharma or non- ▪ Multi- ▪ Pain/No Pain dimensional pharma dimensional • Shazam version option for intervention option
Slide 28: Corporate Summary
CORPO RA TE S UMMARY For personal use only Top shareholders % Financial information Peters Investments Proprietary Ltd 7.2% Share price (30th April 2025) A$0.034 Founders 4.1% Shares on issue 1,841.9m Board & key staff 4.0% Market capitalisation AUD $64.4M Cash (31 March 2024) A$1.6M* Debt Nil Unlis
Slide 29: PainChek Funded to Deliver Inflection Points in CY2025
P AI NC HEK FU ND ED T O D EL IV ER I NFL EC T IO N PO I NT S I N C Y2025 For personal use only 1. US market entry 2. Continued growth 3. Direct to parent of Adult App market entry of the • Achieve Adult App FDA Infant App clearance – target June • Further Penetrate 30th 2025 Aged Care markets • Exp
Slide 30: The Team
THE TEAM For personal use only Philip Daffas Prof. Jeff Hughes Andrew Hoggan Iain McAdam CEO & Managing Chief Scientific Head of Operations CFO Director, MBA, BSc Officer PhD, MPS Philip is a highly accomplished Jeff is a professor in the Andy is a Psychologist, Iain has over 20 years finance & glob
Slide 31: The Board
THE BOARD For personal use only John Murray Philip Daffas Ross Harricks Adam Davey Cynthia Payne Non-Exec Chair CEO & Managing Non-Exec Director Non-Exec Director Non-Exec Director Director 25 years in tech & Philip is a highly Senior global medical Corporate finance 30 years executive Venture Capit
Slide 32: Quarterly update April 2025
For personal use only Q uarterly up date April 2 025 P H I L I P D A F F A S , C EO & M D P A I N C H E K L TD | A S X : PC K 32 |